一例肺癌患者中，Durvalumab同时诱发了抗CRMP-5抗体相关的肿瘤旁系神经病理综合征和神经系统不良事件。
A Case of Lung Cancer Wherein Durvalumab Induced Both Anti-CRMP-5 Antibody-related Paraneoplastic Neurological Syndromes and Neurological Adverse Events.
发表日期：2023 Aug 23
作者：
Tomokazu Seki, Kousuke Baba, Tomohiro Hayashi, Risako Furuta, Hiroaki Hirosawa, Taichi Mitsui, Hiroki Maesaka, Syuhei Takasawa, Toshiro Miwa, Keiko Tanaka, Yuji Nakatsuji
来源：
Brain Structure & Function
摘要：
一名68岁的男性患者被诊断为小细胞肺癌，并在进行durvalumab治疗期间出现了与抗崩解素应答介导蛋白（CRMP）-5抗体相关的肿瘤旁性神经系统疾病（PNS），表现为共济失调和舞蹈病。在激素治疗后，CRMP-5抗体转为阴性，脑磁共振成像上的高信号病灶消失，神经系统症状得到改善。再次使用durvalumab后，患者因神经系统不良反应（nAEs）而无法行走。尚未报道有关同一免疫检查点抑制剂（ICIs）在不同时间点的使用导致PNS和nAEs的病例。在PNS诊断患者中，应谨慎使用ICIs（98/100）。
A 68-year-old man with small-cell lung cancer developed anti-collapsin response-mediator protein (CRMP)-5 antibody-related paraneoplastic neurological syndrome (PNS) presenting with ataxia and chorea during treatment with durvalumab. As a result of steroid therapy, anti-CRMP-5 antibodies became negative, hyperintense lesions on brain magnetic resonance imaging disappeared, and neurological symptoms improved. After resuming durvalumab, he became unable to walk due to neurological adverse events (nAEs). There have been no reported cases manifesting PNSs and nAEs as a result of the same immune checkpoint inhibitors (ICIs) administered at different times. Resuming ICIs in patients diagnosed with PNSs should be performed with prudence. (98/100).